Sarfez Pharmaceuticals, Inc.

This study tested whether an extended-release version of the diuretic torsemide helps heart failure patients get rid of more salt after lunch compared to the standard immediate-release version. Twenty adults with stable heart failure took both forms in a random order, and researc…

This study tested whether an extended-release version of the diuretic torsemide works better than the standard immediate-release form for reducing overactive bladder symptoms in people with chronic heart failure. Twenty-four participants took each version for four weeks, tracking…

This completed Phase 3 trial enrolled 24 healthy adults to see how a new fixed-dose combination tablet containing extended-release torsemide and spironolactone is absorbed and eliminated. Participants took either the combo pill or separate tablets of each drug. Researchers measur…

This completed Phase 3 study in 24 healthy adults examines whether taking a fixed-dose combination of extended-release torsemide and spironolactone with or without food changes how the body absorbs the drugs. Participants receive a single dose under both conditions, and researche…

This study looked at how a new tablet combining two heart failure medicines (torsemide and spironolactone) works in the body compared to taking each drug separately. Twenty-four healthy adults aged 18 to 45 took single doses of the combination or the individual drugs. The goal wa…